Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer

This study has suspended participant recruitment.
Human Genome Center, Institute of Medical Science, University of Tokyo
Information provided by (Responsible Party):
Hiroshi Uchinami, Akita University Hospital Identifier:
First received: February 19, 2008
Last updated: June 22, 2015
Last verified: June 2015
The purpose of this study is to evaluate the safety, tolerability, and immune response of different doses of URLC10 peptide emulsified with Montanide ISA51 in combination with gemcitabine. Recommended phase II dose will be also determined.

Condition Intervention Phase
Bile Duct Cancer
Biological: Peptide vaccine for URLC10
Drug: Gemcitabine
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1 Study of Gemcitabine With Vaccine Therapy Targeting Tumor Antigen, URLC10, For The Patients With Unresectable or Recurrent Bile Duct Cancer

Resource links provided by NLM:

Further study details as provided by Hiroshi Uchinami, Akita University Hospital:

Primary Outcome Measures:
  • Safety (toxicities as assessed by NCI CTCAE version 3) [ Time Frame: 5 years ]

Secondary Outcome Measures:
  • URLC10 peptide specific CTL induction [ Time Frame: 5 years ]
  • DTH to URLC10 peptide [ Time Frame: 5 years ]
  • Changes in levels of regulatory T cells [ Time Frame: 5 years ]
  • Objective response rate as assessed by RECIST criteria [ Time Frame: 5 years ]
  • Time to progression [ Time Frame: 5 years ]
  • Survival rate [ Time Frame: 5 years ]

Estimated Enrollment: 9
Study Start Date: February 2008
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Phase I study Biological: Peptide vaccine for URLC10
Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
Other Name: Gemcitabine
Drug: Gemcitabine
Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.

Detailed Description:

Our previous studies have demonstrated that up-regulated lung cancer 10 (URLC10) has been identified as a new target of tumor associated antigen using cDNA microarray technique combined with the expression profiles of normal and cancer tissues. We have also found that 100% of tissue samples from bile duct cancer express URLC10. We have determined the HLA-A*2402 and HLA-A*0201 restricted epitope peptides derived from URLC10.These epitope peptides have shown to induce specific Cytotoxic T Lymphocytes (CTL). Furthermore, 60% and 20% of Japanese population have HLA-A*2402 and HLA-A*0201, respectively. Therefore, these peptides are suitable for clinical trial. On the other hand, gemcitabine is a drug approved against bile duct cancer. Recent studies has reported that gemcitabine has an additional ability to improve immune response. From these results, synergistic effect between vaccine therapy and chemotherapy using gemcitabine will be expected.

In this clinical trial, we evaluate the safety, tolerability, and immune responses of different doses of URLC10 peptide emulsified with Montanide ISA51 as immunochemotherapy in the patients with unresectable or recurrent bile duct cancer. Toxicity profiles will be monitored, and antigen specific T cell responses will be described.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:


  1. Advanced bile duct cancer precluding curative surgical resection and recurrent bile duct cancer
  2. measurable disease by CT scan, ultrasonography, or other imaging modalities.


  1. ECOG performance status 0-2
  2. Life expectancy >3 months
  3. Laboratory values as follows 2,000/mm³< WBC < 15,000/mm³ Platelet count ≥ 75,000/mm³ Bilirubin ≤ 1.5 x the institutional normal upper limits AST, ALT, ALP ≤ 2.5 x the institutional normal upper limits Creatinine ≤ 1.5 x the institutional normal upper limits
  4. HLA-A*2402 or HLA-A*0201
  5. Able and willing to give valid written informed consent

Exclusion Criteria:

  1. Pregnancy (women of childbearing potential: Refusal or inability to use effective means of contraception)
  2. Breastfeeding
  3. Serious or uncontrolled infection
  4. Prior chemotherapy (except gemcitabine), radiation therapy, or immunotherapy within 4 weeks.
  5. Other malignancy within 5 years prior to entry into the study
  6. Concomitant treatment with steroids or immunosuppressing agent
  7. Disease to the central nervous system
  8. Decision of unsuitableness by principal investigator or physician-in-charge
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00624182

Akita University Hosipital
Akita, Japan, 010-8543
Sponsors and Collaborators
Akita University Hospital
Human Genome Center, Institute of Medical Science, University of Tokyo
Study Chair: Yuzo Yamamoto, MD Department of Gastroenterological Surgery, Akita University, School of Medicine
  More Information


Responsible Party: Hiroshi Uchinami, Gastroenterological Surgery, Akita University Hospital Identifier: NCT00624182     History of Changes
Other Study ID Numbers: AUGIS-001
Study First Received: February 19, 2008
Last Updated: June 22, 2015

Additional relevant MeSH terms:
Bile Duct Neoplasms
Biliary Tract Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Bile Duct Diseases
Biliary Tract Diseases
Digestive System Diseases
Immunologic Factors
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents processed this record on May 25, 2017